ApoGen Biotechnologies, Inc. is a biotechnology startup founded in 2014 and headquartered in the United States. The company focuses on addressing a persistent challenge in cancer treatment - drug resistance. Despite the evolution of cancer therapies, drug resistance remains a significant hurdle, leading to ineffective treatments, recurrence, and decreased survival rates. ApoGen Biotechnologies is developing innovative oncology therapeutics targeting the drivers of mutation and cancer genomic evolution to overcome drug resistance.
The company secured a $4.00M Series A investment on 23 August 2018 from MERL Ventures Fund. This capital injection is indicative of investor confidence in ApoGen Biotechnologies' disruptive approach to combating drug resistance in cancer treatment.
In an industry where innovation is critical, ApoGen Biotechnologies' focus on overcoming an enduring challenge in cancer treatment positions them as a promising player in the biotechnology, healthcare, and pharmaceutical sectors. With innovative therapies in development and solid financial backing, the company is poised to make a meaningful impact in the fight against drug resistance in cancer treatment.
For more information, visit www.apogenbiotech.com
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series A | $4.00M | 1 |
|
23 Aug 2018 |
| Series A | $7.00M | 9 |
|
12 Dec 2016 |
| Pre Seed Round | Unknown | - | 01 Jan 2015 |
No recent news or press coverage available for ApoGen Biotechnologies, Inc..
We care about your data, and we'd love to use cookies make your experience better.
